# **Data Changes for the CCDD FEBRUARY Release Candidate 2022**

## **Based on the QA Release Generation** 20220201

|  |  |
| --- | --- |
| Data entered by | A.Raghuveer |
| Data checked by | J.Hutsul |

## **TM File**

### **Deprecation**

The following TM concept(s) needs to be added back into the TM File with a status of **deprecated**. [Reason for deprecation].

|  |  |  |
| --- | --- | --- |
| **tm\_code** | **tm \_formal\_name** | **tm\_status** |
|  | [NONE] | Deprec |

### **Code permanence – name changes**

The following TM concept(s) need to keep its/their existing tm\_code even though their formal name has changed. [Reason for name change].

|  |  |  |
| --- | --- | --- |
| **tm\_code (to keep)** | **tm \_formal\_name** | **tm\_code in QA Release was** |
|  | [NONE] |  |

### **Concept permanence - returns**

The following TM concept(s) is/are “missing” from the QA Release, but should come back ‘automatically’ in the Release Candidate with a status of “inactive”, when its/their supporting NTPs and MPs will be on the “Whitelist”, as their DINs have been Cancelled Post Market or are Dormant.

|  |  |
| --- | --- |
| **tm\_code** | **tm \_formal\_name** |
|  | [NONE] |

## **NTP File**

### **Deprecation**

The following NTP concept(s) need to be added back into the NTP File with status of **deprecated**.

|  |  |  |  |
| --- | --- | --- | --- |
| **ntp\_code** | **ntp \_formal\_name** | **ntp\_fr\_description** | **ntp\_status** |
| 9000716 | diltiazem hydrochloride 120 mg modified-release oral capsule | chlorhydrate de diltiazem 120 mg capsule orale à libération modifiée | Deprec |
| 9000717 | diltiazem hydrochloride 180 mg modified-release oral capsule | chlorhydrate de diltiazem 180 mg capsule orale à libération modifiée | Deprec |
| 9000718 | diltiazem hydrochloride 240 mg modified-release oral capsule | chlorhydrate de diltiazem 240 mg capsule orale à libération modifiée | Deprec |
| 9000652 | diltiazem hydrochloride 300 mg modified-release oral capsule | chlorhydrate de diltiazem 300 mg capsule orale à libération modifiée | Deprec |

### **Code permanence – name changes**

The following NTP concepts need to keep their existing ntp\_code even though their formal name has changed.

|  |  |  |
| --- | --- | --- |
| **ntp\_code (to keep)** | **ntp \_formal\_name** | **ntp\_code in QA Release was** |
|  | [NONE] |  |

### **Concept permanence – returns check**

The following NTP concepts are “missing” from the QA Release, but should come back ‘automatically’ in the Release Candidate, when their supporting MPs will be on the “Whitelist”, as their DINs have been Cancelled Post Market or are Dormant.

|  |  |
| --- | --- |
| **ntp\_code** | **ntp \_formal\_name** |
| 9013918 | lidocaine hydrochloride 4 % and menthol 1 % cutaneous gel |
| 9000026 | medroxyprogesterone acetate 250 mg per 5 mL suspension for injection vial |
| 9000740 | morphine sulfate 5 mg suppository |

## **MP File**

### **Deprecation (very rare)**

No new deprecated concepts.

### **Deprecation – manual return**

The following MP concepts need to be added back into the MP File with status of **deprecated**. For all DINs, they have had additional UoP added. All products now have new MP.

|  |  |  |  |
| --- | --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_fr\_description** | **mp\_status** |
| 00587737 | HUMULIN N (insulin isophane human 100 unit per mL suspension for injection 10 mL vial) ELI LILLY CANADA INC | HUMULIN N (insuline isophane humaine 100 unité par mL suspension injectable 10 mL fiole) ELI LILLY CANADA INC | Deprec |
| 02182971 | METHOTREXATE INJECTION USP (methotrexate (methotrexate sodium) 1000 mg per 40 mL solution for injection vial) PFIZER CANADA ULC | METHOTREXATE INJECTION USP (méthotrexate (méthotrexate sodique) 1000 mg par 40 mL solution injectable fiole) PFIZER CANADA ULC | Deprec |
| 02182777 | METHOTREXATE INJECTION USP (methotrexate (methotrexate sodium) 500 mg per 20 mL solution for injection vial) PFIZER CANADA ULC | METHOTREXATE INJECTION USP (méthotrexate (méthotrexate sodique) 500 mg par 20 mL solution injectable fiole) PFIZER CANADA ULC | Deprec |
| 02258595 | HUMIRA (adalimumab 40 mg per 0.8 mL solution for injection vial) ABBVIE CORPORATION | HUMIRA (adalimumab 40 mg par 0,8 mL solution injectable fiole) ABBVIE CORPORATION | Deprec |

The following MP concepts are generating as active but need to be set to **deprecated**. For both products, they have been assigned a new DIN (02474891, 02474735). This will have to be done manually each month.

|  |  |  |
| --- | --- | --- |
| **mp\_code** | **mp \_formal\_name** | **mp\_status** |
| 77700322 | METHOTREXATE INJECTION BP (methotrexate (methotrexate sodium) 1000 mg per 40 mL solution for injection vial) ACCORD HEALTHCARE INC | Deprec |
| 77700323 | METHOTREXATE INJECTION BP (methotrexate (methotrexate sodium) 500 mg per 20 mL solution for injection vial) ACCORD HEALTHCARE INC | Deprec |
| 77700627 | DIMENHYDRINATE INJECTION USP (dimenhydrinate 250 mg per 5 mL solution for injection vial) TELIP, LLC, A SUBSIDIARY OF TELIGENT, INC. | Deprec |

### **DPD descriptors**

The following concept(s) needs to have the DPD descriptor added to the brand name to allow differentiation between duplicate mp\_formal names.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| drug\_  code | mp\_code | mp\_formal\_name | DPD descriptor | DPD descriptor - FR |
|  | [NONE] |  |  |  |

### **Concept permanence – manual return**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| drug\_code | mp\_code | mp\_formal\_name | mp\_fr\_description | CCDD status |
|  | [NONE] |  |  |  |

### **Concept permanence – returns check**

The following MPs need to be added to the Whitelist to make sure that they (and their associated NTPs/TMs) continue to be present in the release:

|  |  |  |  |
| --- | --- | --- | --- |
| **drug\_code** | **mp\_code** | **mp\_formal\_name** | **DPD status** |
| 2727 | 382752 | ACETAMINOPHENE 325TAB (acetaminophen 325 mg oral tablet) PRO DOC LIMITEE | cancelled post-market Expiry 2022.01.31 |
| 2728 | 386626 | ACETAMINOPHENE 500TAB (acetaminophen 500 mg oral tablet) PRO DOC LIMITEE | cancelled post-market Expiry 2022.01.31 |
| 83579 | 2350599 | ADVANCE TECHNIQUES KEEP CLEAR 2-IN-1 ANTI-DANDRUFF SHAMPOO (pyrithione zinc 1 % shampoo) THE AVON COMPANY CANADA LIMITED | cancelled post-market Expiry 2022.02.01 |
| 91716 | 2432722 | ALLERGY RELIEF LIQUID GELS (cetirizine hydrochloride 10 mg oral capsule) APOTEX INC | Dormant 2021.11.11 |
| 87690 | 2391570 | BUPROPION SR (bupropion hydrochloride 150 mg prolonged-release oral tablet) SANIS HEALTH INC | cancelled post-market Expiry 2022.01.31 |
| 441 | 30848 | DEPO-PROVERA (medroxyprogesterone acetate 250 mg per 5 mL suspension for injection vial) PFIZER CANADA ULC | cancelled post-market Expiry 2022.01.31 |
| 65132 | 2241492 | DM-DECONGESTANT CHILDREN'S SYRUP (dextromethorphan hydrobromide 7.5 mg per 5 mL and pseudoephedrine hydrochloride 15 mg per 5 mL syrup) TRILLIUM HEALTH CARE PRODUCTS INC | cancelled post-market Expiry 2022.01.31 |
| 72804 | 2248453 | GLICLAZIDE-80 (gliclazide 80 mg oral tablet) PRO DOC LIMITEE | cancelled post-market Expiry 2022.01.31 |
| 97558 | 2485338 | LIDOCAINE PLUS MENTHOL (lidocaine hydrochloride 4 % and menthol 1 % cutaneous gel) THE MENTHOLATUM COMPANY OF CANADA LTD | cancelled post-market Expiry 2022.01.31 |
| 83630 | 2351099 | LORAZEPAM (lorazepam 2 mg oral tablet) SANIS HEALTH INC | cancelled post-market Expiry 2022.01.31 |
| 86045 | 2375052 | MAR-SIMVASTATIN (simvastatin 20 mg oral tablet) MARCAN PHARMACEUTICALS INC | Dormant 2021.12.23 |
| 83602 | 2350815 | MORPHINE SR (morphine sulfate 15 mg prolonged-release oral tablet) SANIS HEALTH INC | cancelled post-market Expiry 2022.01.31 |
| 86794 | 2382075 | MYLAN-BUPROPION XL (bupropion hydrochloride 150 mg prolonged-release oral tablet) MYLAN PHARMACEUTICALS ULC | Dormant 2022.01.12 |
| 18058 | 2148765 | MYLAN-METFORMIN (metformin hydrochloride 500 mg oral tablet) MYLAN PHARMACEUTICALS ULC | cancelled post-market Expiry 2022.01.31 |
| 7442 | 738824 | NOVO-HYDROXYZIN (hydroxyzine hydrochloride 10 mg oral capsule) TEVA CANADA LIMITED | Dormant 2022.01.25 |
| 7443 | 738832 | NOVO-HYDROXYZIN (hydroxyzine hydrochloride 25 mg oral capsule) TEVA CANADA LIMITED | Dormant 2022.01.25 |
| 7444 | 738840 | NOVO-HYDROXYZIN (hydroxyzine hydrochloride 50 mg oral capsule) TEVA CANADA LIMITED | Dormant 2022.01.25 |
| 72108 | 2247814 | RIVA-RANITIDINE 150 (ranitidine (ranitidine hydrochloride) 150 mg oral tablet) LABORATOIRE RIVA INC. | cancelled post-market Expiry 2022.01.31 |
| 72504 | 2248171 | SANDOZ CITALOPRAM (citalopram (citalopram hydrobromide) 40 mg oral tablet) SANDOZ CANADA INCORPORATED | cancelled post-market Expiry 2022.01.31 |
| 74728 | 2261936 | SANDOZ-DICLOFENAC (diclofenac sodium 100 mg suppository) SANDOZ CANADA INCORPORATED | cancelled post-market Expiry 2022.01.31 |
| 51391 | 632228 | STATEX SUPPOSITORIES 5MG (morphine sulfate 5 mg suppository) PALADIN LABS INC. | cancelled post-market Expiry 2022.01.31 |
| 78199 | 2296632 | TEVA-RABEPRAZOLE EC (rabeprazole sodium 10 mg gastro-resistant tablet) TEVA CANADA LIMITED | cancelled post-market 2022.01.26 |
| 78200 | 2296640 | TEVA-RABEPRAZOLE EC (rabeprazole sodium 20 mg gastro-resistant tablet) TEVA CANADA LIMITED | cancelled post-market  2022.01.26 |

## **Blacklist (on GitHub)**

The following changes have been made to the Blacklist for the January 2022 Release Candidate. The list as it is on GitHub should be used.

Changes that have been made to the Blacklist are as follows:  
ACTION is either:

* STAY on Blacklist
* ADD to Blacklist
* REMOVE from Blacklist

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **ntp\_code** | **ntp\_formal\_name** | **drug\_code** | **mp\_code** | **mp\_formal\_name** | **ACTION** |
|  | lidocaine 0.8 % cutaneous gel | 98886 | 02499118 | AFTER SUN GEL (lidocaine 0.8 % cutaneous gel) FRUIT OF THE EARTH, INC | STAY |
|  | fluorouracil 500 mg per 10 mL solution for injection vial | 96316 | 02473763 | FLUOROURACIL INJECTION (fluorouracil 500 mg per 10 mL solution for injection vial) BIOLYSE PHARMA CORPORATION | REMOVE |